One Case of Severe Anaphylaxis Shock Induced by Tranexamic Acid Injection

Abstract

CLC Number:

R994.11

WANG Yiting, LI Weiwei, XIE Jingwen, GAO Min, LI Xiaoyan. One Case of Severe Anaphylaxis Shock Induced by Tranexamic Acid Injection[J]. Chinese Journal of Pharmacovigilance, 2018, 15(8): 501-502.

[1] 李博,高蕊,李睿,等. 药物临床试验不良反应/不良事件关联性判定方法研究探讨[J]. 中国新药杂志, 2014,23(12):1465-1470.
[2] Berry L L, Segal R, Sherrin T P, et al.Sensitivity and specificity of three methods of detecting adverse drug reactions[J]. Am J Hosp Pharm, 1988, 45(7):1534-1539.
[3] 魏晶,王瑜歆. 药品不良反应报告因果关系评价方法概述[J]. 中国药物警戒, 2011, 08(10):600-603.
[4] 杨华, 魏晶, 王嘉仡,等. 药品不良反应/事件报告评价方法研究[J]. 中国药物警戒, 2009, 6(10):581-584.
[5] Dunn C J, Goa K L.Tranexamic acid: a review of its use in surgery and other indications.[J]. Drugs, 1999, 57(6):1005-1032.
[6] Lucaspolomeni M M, Delaval Y, Menestret P, et al.A case of anaphylactic shock with tranexamique acid (Exacyl)[J]. Annales Francaises Danesthesie Et De Reanimation, 2004, 23(6):607-609.
[7] 张强. 氨甲环酸致过敏反应2例[J]. 中国药师, 2004, 7(8):598-598.
[8] 魏雪梅, 张晋萍. 氨甲环酸注射液致严重过敏反应[J]. 药物不良反应杂志, 2005, 7(2):145-145.
[9] 王金明. 氨甲环酸注射液的不良反应[J]. 江西医药, 2007, 42(3):273-274.
[10] 马玉莲. 氨甲环酸引起过敏性休克一例报告[J]. 青海医药杂志, 2010, 40(7):78-78.
[11] 金秋芳. 氨甲环酸致严重过敏反应1例报告[J]. 实用医院临床杂志, 2010, 07(6):146-146.
[12] 黄荣富, 苏静, 胡忠杰. 氨甲环酸致过敏性休克1例[J]. 中国医院药学杂志, 2011,31(4):344-344.
[13] 串俊兰, 吕晶, 韩勇. 氨甲环酸致不良反应个例报道文献分析[J]. 中国药师, 2013, 16(3):456-458.
[14] 刘产明, 朱月琴, 曾晓辉. 氨甲环酸氯化钠注射液引起过敏性休克的系统评价[C]//江苏省药学大会暨江苏省药师周. 2011.
[15] Imbesi S, Nettis E, Minciullo P L, et al.Hypersensitivity to tranexamic acid: a wide spectrum of adverse reactions[J]. Phar World Sci, 2010, 32(4):416-419.
[16] Calapai G.Systematic Review of Tranexamic Acid Adverse Reactions[J]. J Pharmacovigilance, 2015,3(4):171-177.
[17] 王道祥, 江腊梅, 王京娥,等. 86例药源性过敏性休克不良反应分析[J]. 中国药物警戒, 2010, 7(5):303-305.
[18] 刘仕娟. 滴速控制在减轻氨甲环酸氯化钠注射液不良反应中的应用[J]. 临床合理用药杂志, 2011, 4(30):61-62.

One Case of Severe Anaphylaxis Shock Induced by Tranexamic Acid Injection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.